Has AMWELL gone too high too fast?
Like many tech companies, AMWL has grown at an exponential rate while remaining unprofitable. Is there a path to profitability? Sure.
avatar
Mike Sakuraba graduated with double major of English and Economics. Part time writer, part time investor, full time dad. Mike loves writing about technology, sports, and investing.
2020-10-12 10:14

The COVID-19 pandemic has been crippling to many industries but tele-medicine is certainly not one of them. In fact, industry leader Teladoc (NYSE:TDOC) has seen its shares climb over 150% since the beginning of the year, something recent IPO American Well or AMWELL (NYSE:AMWL) is hoping to replicate. The sector is not overcrowded by any means, but tele-medicine has been at the forefront of methods in continuing essential medical services during the global pandemic. The premise is simple: a majority of medical visits need not be in person anymore and while this is something that has been crucial during this pandemic, there certainly is a chance that this continues as a new normal in the future.

Has AMWELL gone too high too fast?

If you have not heard of AMWL, you are not alone. Most investors are familiar with TDOC and how established it is as the leader in this field. After the much publicized announcement of the merger with Livongo Health (NASDAQ:LVGO), TDOC has been on the radar of investors for a better part of this year. Well, AMWL should be on your radar as well if you think that virtual health visits are the way of the future. First, AMWL is extremely popular amongst its users and was recently rated as the number one telemedicine platform in America. Secondly, it is growing and it is growing fast. In the first six months of 2020, AMWL’s revenues grew by nearly 80% year-over-year and with that came a massive rise in monthly visits. Third, it has an incredibly powerful backer: Alphabet, the parent company of Google (NASDAQ:GOOGL) which threw down $100 million in investments. That is some serious cash from the biggest name in the tech space.

Like many tech companies, AMWL has grown at an exponential rate while remaining unprofitable. Is there a path to profitability? Sure. But right now they are stuck in that high growth high spend phase that so many new companies go through. The stock price has jumped nearly 70% since it went public, not even one month ago. We know how popular these new IPO stocks are, but the current valuation is nearly twenty times its trailing annual sales which is a fairly high valuation for a recently public company. But AMWL has some positives too including a fairly squeaky clean balance sheet with very little debt compared to its cash on hand.

Is there space for more than one dominant telemedicine company in the space? Of course. The total addressable market for this sector is anyone who needs to see a physician. Period. AMWL should continue to grow its client base, and rest assured, it is not just investors that are eyeing this opportunity. Recently, rumors of AMWL being acquired by UnitedHealth Group (NYSE:UNH) has raised the eyebrows of more than a few people on Wall Street. Listen, UnitedHealth is the largest healthcare company in the world by revenue, and if companies like this and Alphabet are chomping at the bit to get involved with AMWL, it is often a good sign that investors should too.


Disclaimer: I am long on AMWL. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article. All information should be independently verified and should not be relied upon for purposes of transacting securities or other investments. See terms for more info.

Rate this article

positive
negative
Published On
2020-10-12 10:14

avatar
About the Author
Mike Sakuraba graduated with double major of English and Economics. Part time writer, part time investor, full time dad. Mike loves writing about technology, sports, and investing.


buy-coffee
You've read 1 article in the last year
..thank you for supporting us and for visiting our site. Unlike many other sites, The Dog of Wall Street is available for everyone to read. Our focus is to provide great content for free. Do you like what we are doing? Buy us a cup coffee. It is the fuel that keeps us going..

Levi Strauss' Bold Gambit: Is the Denim Icon's DTC Shift Enough to Weather the Storm?
Levi Strauss & Co. boasts a strong quarter with direct-to-consumer growth and innovative fashion, but can it navigate the choppy waters of the retail market?
By Alfonso | 9 months ago

Amazon's Bold Counterattack: Introducing the China-Direct Discount Section
As competition heats up, Amazon unveils a daring new strategy to offer unbeatable prices and direct shipping from China.
By Alfonso | 9 months ago

Tesla's Legal Challenges: Facing the Music on Autopilot Misrepresentation
Court ruling intensifies scrutiny on Tesla's self-driving claims.
By Alfonso | 10 months ago

Netflix's Ad-Supported Triumph: A New Era in Streaming
Surpassing 40 million users, Netflix’s ad-supported plan redefines the streaming landscape.
By Alfonso | 10 months ago

Tesla Stock (TSLA): Look Who's Back!
I’m cautiously optimistic but I’m at the point where I need to see it to believe it.
By Mike Sakuraba | 11 months ago

2 Earnings To Pay Attention to Next Week
Since big tech is the theme, you probably know what I have my eyes on for next week.
By Mike Sakuraba | 11 months ago

2 Stocks to Watch Below $10
Here are two stocks that are currently less trading in the single digits that I believe have some relative upside from their current prices.
By Mike Sakuraba | 11 months ago

Looking Ahead to Tesla's Earnings: What Can We Expect?
Is there any stock that has been more talked about than Tesla (NASDAQ: TSLA) as of late? It’s a company that is always in the spotlight but the stock is under some heavy scrutiny this year and deservedly so.
By Mike Sakuraba | 11 months ago